Overview

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

Status:
Completed

Trial end date:
2015-11-02

Target enrollment:

Participant gender:

Summary

This study was designed to evaluate the cognitive effect, safety, and pharmacokinetics (PK) of rufinamide on Lennox-Gastaut Syndrome (LGS) inadequately controlled in pediatric participants already taking other anti-epileptic drugs.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Anticonvulsants
Rufinamide